Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway

Experimental Cell Research

Volumn 295, Issue 1, 2004, Pages 245-257

  Quintanilla, Rodrigo A ^b   Orellana, Daniel I ^b   González Billault, Christian ^b   Maccioni, Ricardo B ^a  

^a Iniciativa Cientifica Milenio Santiago   (Chile)

^b NONE

Author keywords

Alzheimer disease; Amyloid beta peptide; A ; cdk5 p35; Cytokines; IL 6; IL 6 receptor; IL 6R; Interleukin 6; MAPK p38; PDPKs; Proline dependent protein kinases; Tau protein

Indexed keywords

BUTYROLACTONE; CYCLIN DEPENDENT KINASE 5; EPITOPE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLINE DIRECTED PROTEIN KINASE; PROTEIN KINASE; PROTEIN P35; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; HIPPOCAMPUS; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

EID: 1642420308     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.01.002     Document Type: Article

References (59)

1. Gadient R.A., Otten U.H. Interleukin-6 (IL-6) - A molecule with both beneficial and destructive potentials. Prog. Neurobiol. 52:2002;379-390.
2. Akama K.T., Van Eldik L.J. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J. Biol. Chem. 275:2000;7918-7924.
3. Bauer J., Strauss S., Volk B., Berger M. IL-6-mediated events in Alzheimer's disease pathology. Immunol. Today. 12:1991;422.
4. Bauer Strauss J.S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:1991;111-114.
5. Ganter U., Strauss S., Jonas U., Weidemann A., Beyreuther K., Volk B., Berger M., Bauer J. Alpha 2-macroglobulin synthesis in interleukin-6-stimulated human neuronal (SH-SY5Y neuroblastoma) cells. Potential significance for the processing of Alzheimer beta-amyloid precursor protein. FEBS Lett. 282:1991;127-131.
6. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202:1995;17-20.
7. Jones S., Horiuchi S., Topley N., Yamamoto N., Fuller G. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15:2001;43-58.
8. Campbell I., Stadler A., Atwa Y., Pagenstecher A., Asensio V. Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation. 5:1998;126-135.
9. Ershler W.B., Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases and frailty. Ann. Rev. Med. 51:2000;245-270.
10. Del Bo R., Angeretti N., Lucca E., De Simoni M.G., Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci. Lett. 188:1995;70-74.
11. Blasko I., Veerhuis R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P., Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol. Dis. 7:2000;682-689.
12. Gitter B.D., Cox L.M., Rydel R.E., May P.C. Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10738-10741.
13. Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 61:1997;2323-2333.
14. Mehlhorn G., Hollborn M., Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18:2000;423-431.
15. Apelt J., Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 894:2001;21-30.
16. Tehranian R., Hasanvan H., Iverfeldt K., Post C., Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci. Lett. 301:2001;54-58.
17. Toro V.C., Tehranian R., Zetterstrom M., Eriksson G., Langel U., Bartfai T., Iverfeld K. Increased gene expression of interleukin-1alpha and interleukin-6 in rat primary glial cells induced by beta-amyloid fragment. J. Mol. Neurosci. 17:2001;341-350.
18. Luterman J.D., Horoutunian V., Yemul S., Ho L., Purohit D., Aisen P.S., Mohs R., Pasineti G.M. Cytokine gene expression as a function of the clinical progression of Alzheimer's disease dementia. Arch. Neurol. 57:2000;1153-1160.
19. Heyser C.J., Masliah E., Samimi A., Campbell I.L., Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1500-1505.
20. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32:2001;367-381.
21. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23:2003;1605-1611.
22. Alvarez A., Toro R., Cáceres A., Maccioni R.B. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 459:1999;421-426.
23. Alvarez A., Munoz J.P., Maccioni R.B. A cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of cdk5 activity in hippocampal neurons. Exp. Cell Res. 264:2001;266-274.
24. Ohshima T., Ward J.M., Huh C.G., Longenecker G., Veeranna, Pant H.C., Brady R.O., Martin L.J., Kulkarni A.B. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11173-11178.
25. Chae T., Kwon Y.T., Bronson R., Dikkes P., Li E., Tsai L.H. Mice lacking p35, a neuronal specific activator of cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron. 18:1997;29-42.
26. Tsai L.H., Delalle I., Caviness V.S., Chae T., Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 371:1994;419-423.
27. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453:1999;260-264.
28. Humbert S., Dhavan R., Tsai L.H. p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J. Cell Sci. 113(Pt 6):2000;975-983.
29. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
30. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622.
31. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., Nelson R.B., McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2910-2915.
32. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
33. Rapoport M., Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J. Neurochem. 74:2000;123-125.
34. Karasewski L., Ferreira A. MAPK signal transduction pathway mediates agrin effects on neurite elongation in cultured hippocampal neurons. J. Neurobiol. 55:2003;14-24.
35. Banker G.A., Cowan W.M. Rat hippocampal neurons in dispersed cell culture. Brain Res. 126:1977;342-397.
36. Bottenstein J.E., Sato G.H. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc. Natl. Acad. Sci. U. S. A. 76:1979;514-517.
37. Giovannini M.G., Scali C., Prosperi C., Bellucci A., Vannucchi M.G., Rosi S., Pepeu G., Casamenti F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis. 11:2002;257-274.
38. Kim M.S., Sung M.J., Seo S.B., Yoo S.J., Lim W.K., Kim H.M. Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. Neurosci. Lett. 321:2002;105-109.
39. Sharma P., Veeranna, Sharma M., Amin N.D., Sihag R.K., Grant P., Ahn N., Kulkarni A.B., Pant H.C. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J. Biol. Chem. 277:2002;528-534.
40. Rolli-Derkinderen M., Machavoine F., Baraban J.M., Grolleau A., Beretta L., Dy M. ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1. J. Biol. Chem. 2003 (March 4);. (e-publication ahead of print).
41. De Jaco A., Augusti-Tocco G., Biagioni S. Muscarinic acetylcholine receptors induce neurite outgrowth and activate the synapsin I gene promoter in neuroblastoma clones. Neuroscience. 113:2002;331-338.
42. Odonovan K., Toursellotte W., Milhrant J., Baraban J. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci. 22:1999;167-173.
43. Rolli-Derkinderen M., Gaestel M. p38/SAPK2-dependent gene expression in Jurkat T cells. J. Biol. Chem. 381:2000;193-198.
44. Harada T., Morooka T., Ogawa S., Nishida E. ERK induces p35, a neuron-specific activator of cdk5, through induction of Egr1. Nat. Cell Biol. 3:2001;453-459.
45. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A.L., Zhu X., Raina A.K., Holbrook N., Siedlak S.L., Harris P.L.R., Smith M.A. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport. 10:1999;2411-2415.
46. Zhu X., Rottkamp C.A., Boux H., Takeda A., Perry G., Smith M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59:2000;880-888.
47. Zhu X., Castellani R.J., Takeda A., Nunomura A., Atwood C.S., Perry G., Smith M.A. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the "two hit" hypothesis. Mech. Ageing Dev. 123:2001;39-46.
48. Gijbels K., Van Damme J., Proost P., Put W., Carton H., Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 20:1990;233-235.
49. Schobitz B., de Kloet E.R., Sutanto W., Holsboer F. Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur. J. Neurosci. 5:1993;1426-1435.
50. Otth C., Concha I.I., Arendt T., Stieler J., Schliebs R., Gonzalez-Billault C., Maccioni R.B. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimer's Dis. 4:2002;417-430.
51. Hu J., Van Eldik L.J. Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation. Brain Res. 842:1999;46-54.
52. Fiebich B.L., Schleicher S., Spleiss O., Czygan M., Hull M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem. 79:2001;950-958.
53. Qiu Z., Sweeney D.D., Netzeband J.G., Gruol D.L. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J. Neurosci. 18:1998;10445-10456.
54. Gandy S., Czernik A.J., Greengard P. Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin- dependent protein kinase II. Proc. Natl. Acad. Sci. U. S. A. 85:1988;6218-6221.
55. Cadman E.D., Witte D.G., Lee C.M. Regulation of the release of interleukin-6 from human astrocytoma cells. J. Neurochem. 63:1994;980-987.
56. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275:2000;17166-17172.
57. Kerokoski P., Suuronen T., Salminen A., Soininen H., Pirttila T. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation. Biochem. Biophys. Res. Commun. 298:2002;693-698.
58. Bagli M., Papassotiropoulos A., Knapp M., Jessen F., Rao M.L., Maier W., Heun R. Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci. Lett. 283:2000;109-112.
59. Bhojak T.J., DeKosky S.T., Ganguli M., Kamboh M.I. Genetic polymorphisms in the cathepsin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci. Lett. 288:2000;21-24.